Print

Peritoneal Dialysis

 

Peritoneal dialysis is a suitable option for most patients requiring renal replacement therapy. It allows individuals to play a key role in therapy whilst remaining in a familiar home environment.

As part of our commitment to supporting patients and their carer’s, Fresenius Medical Care has developed the P3 program. The core goal of this program is to support users to protect, preserve and prolong the peritoneal membrane throughout all aspects of peritoneal dialysis therapy – thereby improving their quality of life while aiming to extending their time on peritoneal dialysis.

The P3 programme ensures that, Fresenius Medical Care is well positioned to support local clinicians to provide ongoing, individualise patient centred peritoneal dialysis therapy through the delivery of:

  • Protect: unique and easy-to-understand peritoneal dialysis systems
  • Preserve: peritoneal membrane through reduced exposure to glucose degradation products (GDP)
  • Prolong: individual state-of-the art therapies for fluid balance control and guided prescription modeling

Protect

Our peritoneal dialysis systems have a unique design and are convenient to use while improving patient compliance. Supported by environmentally friendly materials that are PVC-free, these systems allow maximum flexibility in prescription management.

Preserve

Reduced exposure to glucose degradation products has been associated with preserving the peritoneal membrane and low infection rates. 1

Prolong

Our simple, reliable hydration status assessment with the Body Composition Monitor (BCM) together with the guided prescription modelling of PatientOnLine to individually adjust therapy can help to prolong time on PD. Incorporating the Adapted Automated Peritoneal Dialysis (aAPD) treatment concept may enhance small solute clearance, and improve peritoneal ultrafiltration without increasing metabolic glucose load or additional cost or resources. 2

Fresenius Medical Care PD systems offer the flexibility to meet the changing needs of the patients over time.

Continuous Ambulatory Peritoneal Dialysis (CAPD)

– patients perform multiple exchanges over a 24 hour period which results in the peritoneal membrane always being in contact with peritoneal dialysis fluid.

Automated Peritoneal Dialysis (APD)

– patients usually perform therapy overnight. A cycler is used to perform the exchanges. The sleep•safe cycler has the flexibility to deliver a variety of therapies as outlined below including;

  • Automated PD Plus - a combined day time exchange and overnight exchanges.
  • Adapted APD - a sleep•safe cycler is used to incorporate cycles of different dwell length and fill volume to facilitate improved small molecule clearance and increase peritoneal membrane ultrafiltration. 2

In patients with declining residual renal function and decreasing transport properties of the peritoneum, it may be necessary to consider an alternative to peritoneal dialysis.

References

  1. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan SH, Voss D; balANZ Trial Investigators. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol. 2012 Jun;23(6):1097-107. Epub 2012 Mar 22. PubMed PMID: 22440906.
  2. Fischbach M, lssad B, Dubois V, Taamma R. The beneficial influence on the effectiveness of automated peritoneal dialysis of varying the dwell time (short/Iong) and fill volume (small/Iarge): a randomized controlled trial. Peri Dial lnt 2011; 31(4):450-8

For further information on the P3 program, please contact us at enquiry.SG@fmc-asia.com or +65 6837 3113


p 3 cube